Adrenocortical carcinoma - a diagnostic and therapeutic challenge

Authors

  • Sofia Broco Serviço de Oncologia Médica - Instituto Português de Oncologia de Coimbra Francisco Gentil E.P.E
  • Nuno Bonito Serviço de Oncologia Médica - Instituto Português de Oncologia de Coimbra Francisco Gentil E.P.E
  • Gabriela Sousa Serviço de Oncologia Médica - Instituto Português de Oncologia de Coimbra Francisco Gentil E.P.E
  • Helena Gervásio Serviço de Oncologia Médica - Instituto Português de Oncologia de Coimbra Francisco Gentil E.P.E

Keywords:

adrenocortical carcinoma, mitotane, chemotherapy

Abstract

Adrenal cortical cancer is a rare and aggressive neoplasm with
dismal prognostic.
Its pathogenesis is still incompletely understood. Most of them
seem to be sporadic but there are some hereditary syndromes
described in association.
There are no specific features that characterize this malignancy.
Heterogeneity of clinical, laboratorial, imaging and pathological
findings makes this diagnosis a challenge, even to an experient
multidisciplinary team.
The only chance of cure is still surgery, when a complete resection is possible. There is no medical treatment that convincingly
demonstrates optimal results in advanced disease.
Progresses will come in the future, from a better understanding
of molecular mechanisms of adrenal tumorigenesis.
The authors made a review of epidemiology, pathogenesis,
diagnostic, management and prognostic factors aspects and
illustrate with two distinct clinical cases.

Downloads

Download data is not yet available.

References

Libé R, Fratticci A, Beryherat J. Adrenocortical cancer : pathophysiology and clinical management. Endocr Relat Cancer 2007; 14(1) :13-28.

Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12(3):667-680.

Allolio B, Hahner S, Weismann D, Fassnacht. Management of adrenocortical carcinoma. Clin Endocrinol 2004; 60(3):273-287.

Savarese D, Nieman L. Clinical presentation and evaluation of adrenocortical tumours. Uptodate. Utdonline

Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical Update. J Clin Endocrinol Metab 2006; 91(6):2027-2037.

Wajchenberg B, Pereira M, Mendonça B, Latronico A, Carneiro P et al. Adrenocortical carcinoma- clinical and laboratorial observations. Cancer 2000; 88(4): 711-736.

Chouairy CJ, Abdul-Karim F, MacLennan GT. Adrenocortical carcinoma. J Urol 2008; 179(1):323.

Bertagna X. Adrenal Cancer. Editions John Libbey Paris 2006.

Kuruba R, Gallagher S. Current management of adrenal tumors. Curr Opin Oncol. 20(1):34-46.

Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors 1984; 8 (3):163-240.

Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol. 1978 Dec;120(6):660-665.

Goetz MP, Callstrom MR, Charboneau JW et al. Percutaneous image-guided radiofrequency ablation of painful metastasis involving bone: a multicenter study. J Clin Oncol 2004; 15; 22(2):300-306.

Bergenstal DM, Hertz R, Lipsett MB, Moy RH. Chemotherapy of adrenocortical cancer with o,p’-DDD. Ann Intern Med 1960; 53 (4): 672-682.

Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res. 2000 ;33(10):1197-1200.

Ahlaman H, Khorram-Manesh A, Janssom S, Wängberg B, Nilsson O et al. Cytotoxic treatment of adrenocortical carcinoma. World J Surg 2001, 25(7): 927-933.

Abiven G, Coste J, Groussin L, Anract P, Tissier F et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006; 91(7):2650-2655.

Fassnacht M, Hahner S, Polat B, Koschner A, Kenn W, Flentj M, Allolio B. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91(11):4501-4504.

Bates SE, Shieh CY, Mickley LA, Dickek HL, Loriaux DL, Fojo AT. Mitotane enhances citotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene MDR-1/pglycoprotein which is also expressed by adrenocortical carcinoma. J Clin Endocrinol Metab 1991;73(1):18-29.

Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L, Mitotane associated with etoposide, doxorubicin and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the study of Adrenal Cancer. Cancer 1998; 83 (10):2194-2200.

Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12(3):657-666.

Khan TS, Imam H, Juhlin C, Skogseid B, Gröndal S, et al. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 2000 ;11(10):1281-1287.

Quinkler M, Hahner S, Wortmann S, Johanssen E, Adam P et al. Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine. J Clin Endocrinol Metab. 2008;93(6):2057-2062.

Assié G, Antoni G, Tissier F, Cailllou B, Abiven G, Gicquel C et al. Prognostic Parameters of Metastatic Adrenocortical Carcinoma. J Clin Endocrinol Metab 2007; 92(1):148-154

Additional Files

Published

2010-03-31

How to Cite

1.
Broco S, Bonito N, Sousa G, Gervásio H. Adrenocortical carcinoma - a diagnostic and therapeutic challenge. RPMI [Internet]. 2010 Mar. 31 [cited 2024 Dec. 18];17(1):65-7. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/1281

Issue

Vol. 17 No. 1 (2010): Janeiro/ Março

Section

Review Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Medicina Interna

Open Access

Most read articles by the same author(s)